Ctrl Therapeutics Launches With $10M Seed Financing To Advance Next-Generation Cell Therapy Platform For The Treatment Of Solid Tumors

Apr 10, 2023•over 2 years ago

Amount Raised

$10 Million

Round Type

seed

ChicagoTherapeuticsHealth CareBiotechnology

Investors

FacitIntermountain HealthGeneral Catalyst

Description

CTRL Therapeutics Inc., a biotechnology company developing a next-generation cell therapy platform for solid tumors, today announced a $10M seed financing led by General Catalyst with participation from Intermountain Health, FACIT and other investors.

Company Information

Company

CTRL Therapeutics

Location

655 SHERIDAN RD

Chicago, Illinois, United States

About

CTRL Therapeutics is a biotechnology company developing a next-generation cell therapy platform with the potential to unlock a new frontier in cell therapy for solid tumors. With broad applicability across numerous solid tumors, the company's proprietary approach for the identification and isolation of circulating tumor-reactive lymphocytes (cTRLs) has the potential to address longstanding challenges associated with cell therapy and offers key advantages over tumor-infiltrating lymphocytes (TILs). For more information, visit www.ctrl-therapeutics.com.

Related People

4 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends